Tesla勁敵Lucid計劃10月底交車
Tesla(TSLA.US)勁敵、專攻豪華車型的Lucid(LCID.US)宣佈,將於10月底交車,首款交付的車型是Lucid Air Dream Edition,售價16.9萬美元,計劃將生產520輛,而公司入門款車型Lucid Air售價7.74萬美元,目前已收到超過1.3萬份訂單。
Lucid爲首間透過特殊目的收購公司(SPAC)方式上市的電動車創新公司,自從7月在納斯達克上市後,便被視爲Tesla的主要競爭者。而在本月初,Lucid透露旗下Lucid Air Dream車型的續航裏程獲得美國環境保護署(EPA)認證,達至約836.8公裏,比Tesla的Model S續航版型號還多約160.9公裏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.